×
About 42,803 results

ALLMedicine™ Anemia Center

Research & Reviews  14,642 results

Impact of telehealth visits on hydroxyurea response in sickle cell anemia.
https://doi.org/10.1002/pbc.29354
Pediatric Blood & Cancer; Sarah S, Lee H et. al.

Sep 18th, 2021 - It is important to ensure access to hydroxyurea (HU) for patients with sickle cell anemia (SCA) living in rural areas. The University of Alabama at Birmingham (UAB) Pediatric Sickle Cell program's satellite clinics reduce the barrier of transporta...

HSCT remains the only cure for patients with transfusion-dependent thalassemia until ge...
https://doi.org/10.1038/s41409-021-01461-0 10.1038/gim.2016.173 10.1016/S0140-6736(17)31822-6 10.1111/nyas.13088 10.1016/j.bbmt.2020.03.016 10.1111/bjh.17335 10.1517/21678707.2015.1076724 10.1038/bmt.2011.39 10.1016/j.bbmt.2011.01.012 10.1111/j.1365-2141.2011.08598.x 10.3324/haematol.2017.183467 10.3324/haematol.2018.196071 10.1016/j.bbmt.2017.06.004 10.1515/JPEM.2005.18.5.477 10.1038/bmt.2017.214 10.1097/MOH.0000000000000581 10.1016/j.exphem.2018.05.004 10.1002/cpt.1639 10.1038/sj.bmt.1705193 10.1097/00043426-200210000-00019 10.1196/annals.1345.023 10.1038/sj.bmt.1705173 10.1182/blood.V99.12.4350 10.1111/nyas.13019 10.1002/pbc.24493 10.1182/blood-2009-05-218982 10.1016/j.bbmt.2013.04.023 10.1097/TP.0000000000000928 10.1016/j.bbmt.2012.11.007 10.1016/j.phoj.2017.05.001 10.1182/blood-2012-04-423822 10.1371/journal.pone.0061637 10.1016/j.bbmt.2019.03.028 10.1038/bmt.2011.219 10.1111/petr.13209 10.1182/asheducation-2018.1.361 10.1038/s41409-019-0598-x 10.1097/MOH.0000000000000280 10.1038/sj.bmt.1702242 10.1182/blood-2013-07-513473 10.1182/bloodadvances.2017012005 10.1038/sj.bmt.1704572 10.1111/j.1399-3046.2007.00844.x 10.1016/j.bbmt.2020.01.002 10.1038/bmt.2016.7 10.1111/bjh.15438 10.1016/S2352-3026(19)30031-6 10.1056/NEJMoa1705342 10.1038/nature09328 10.1038/s41591-018-0301-6 10.1016/j.bbmt.2019.12.588 10.1038/s41576-020-00298-5 10.3389/fped.2019.00443 10.1007/s40259-020-00439-6 10.1182/blood-2017-10-811505 10.1182/bloodadvances.2019000820 10.1038/s41467-019-12726-0 10.1097/HS9.0000000000000479 10.1002/ajh.25909 10.1182/blood-2013-05-502658 10.1182/blood-2019-126239
Bone Marrow Transplantation; Oikonomopoulou C, Goussetis E

Sep 18th, 2021 - Patients with β-thalassemia suffer from severe anemia, iron overload and multiple complications, that affect their quality of life and well-being. Allogeneic hematopoietic stem cell transplantation (HSCT) from an HLA-matched sibling donor, perform...

Epidemiological shift of glucose-6-phosphate dehydrogenase mutations in northern Italy ...
https://doi.org/10.1007/s00277-021-04630-9 10.1016/j.bcmd.2008.12.005 10.1182/blood.2019000944 10.1016/S0140-6736(08)60073-2 10.1016/j.ijbiomac.2017.06.002 10.1007/BF00219681 10.1053/beha.1999.0056 10.1182/blood.V54.5.961.961 10.1046/j.1365-2141.2002.03483.x 10.1080/10245332.2016.1276117 10.1016/j.hoc.2015.11.006 10.1007/s00439-005-0126-5
Annals of Hematology; Duca L, Nava I et. al.

Sep 18th, 2021 - Glucose-6-phosphate dehydrogenase (G6PD) deficiency is an X-linked recessive hemolytic anemia caused by mutations in G6PD gene. The distribution and frequency of genetic variants differ depending on ethnicity and geographical areas. Because of new...

Iron deficiency and biomarkers of inflammation: a 3-year prospective analysis of the DO...
https://doi.org/10.1007/s40520-021-01955-3 10.1007/s40520-019-01454-6 10.1182/blood-2012-09-453522 10.1016/j.bbi.2018.02.013 10.1172/JCI20945 10.1002/ajh.24820 10.1007/s10354-016-0505-7 10.1590/1414-431x20198392 10.5551/jat.16071 10.1038/s41569-018-0064-2 10.1016/j.ejim.2017.04.018 10.14740/jocmr2959w 10.2147/cia.S90727 10.1186/s12979-019-0168-5 10.1186/s12979-019-0170-y 10.1007/s11357-011-9341-2 10.1111/j.1532-5415.2011.03570.x 10.12669/pjms.35.2.520 10.1016/j.mad.2013.11.005 10.3389/fphar.2014.00083 10.1016/j.cct.2020.106124 10.1111/trf.15577 10.1002/ajh.10014 10.1007/s00277-005-1033-5 10.1155/2012/646201 10.1016/j.bbagen.2010.03.011 10.1016/0002-9343(90)90143-2 10.4414/smw.2017.14434 10.1001/archinte.162.4.445 10.1002/art.10993 10.1093/gerona/56.3.m146 10.1093/ije/23.5.991 10.1016/j.jamda.2013.05.009 10.1038/s41572-018-0014-7 10.1136/tobaccocontrol-2019-054958 10.20524/aog.2017.0152 10.3748/wjg.v22.i35.7908 10.1681/ASN.2019020213 10.1159/000496492 10.1186/s12979-016-0076-x 10.1182/blood-2006-06-027631 10.1016/j.ejim.2016.07.020 10.1016/j.eurger.2012.06.005 10.1093/gerona/gly028 10.1007/s00005-015-0357-7 10.1503/cmaj.122072 10.1016/j.amjmed.2005.01.065
Aging Clinical and Experimental Research; Wieczorek M, Schwarz F et. al.

Sep 18th, 2021 - The longitudinal association between iron deficiency and inflammatory biomarkers levels has not been fully explored among relatively healthy older adults. To assess whether iron deficiency at baseline and at any yearly follow-up time point, with o...

Cefoperazone/sulbactam-induced hemolytic anemia.
https://doi.org/10.4103/jpgm.JPGM_1335_20
Journal of Postgraduate Medicine; Sun XM, Liu LH et. al.

Sep 17th, 2021 - Drug-induced hemolytic anemia (DIHA) is a rare complication of drug therapy and usually underdiagnosed. Cefoperazone/sulbactam is a compound prepared from the third generation of cephalosporin and β-lactamase inhibitor. There are limited data of D...

see more →

Guidelines  25 results

Controversies in optimal anemia management: conclusions from a Kidney Disease: Improvin...
https://doi.org/10.1016/j.kint.2021.03.020
Kidney International; Babitt JL, Eisenga MF et. al.

Apr 12th, 2021 - In chronic kidney disease, anemia and disordered iron homeostasis are prevalent and associated with significant adverse consequences. In 2012, Kidney Disease: Improving Global Outcomes (KDIGO) issued an anemia guideline for managing the diagnosis,...

GI Evaluation of Iron Deficiency Anemia: Clinical Decision Support Tool.
https://doi.org/10.1053/j.gastro.2020.08.043
Gastroenterology

Aug 31st, 2020 - GI Evaluation of Iron Deficiency Anemia: Clinical Decision Support Tool.|2020| ,|blood,diagnosis,etiology,standards,methods,standards,standards,diagnostic imaging,metabolism,pathology,standards,blood,complications,diagnosis,pathology,analysis,diag...

Spotlight: Gastrointestinal Evaluation of Iron Deficiency Anemia.
https://doi.org/10.1053/j.gastro.2020.08.036
Gastroenterology Ko CW, Siddique SM et. al.

Aug 31st, 2020 - Spotlight: Gastrointestinal Evaluation of Iron Deficiency Anemia.|2020|Ko CW,Siddique SM,Patel A,Harris A,Altayar O,|blood,diagnosis,etiology,standards,standards,standards,diagnostic imaging,metabolism,pathology,standards,blood,complications,diagn...

AGA Clinical Practice Guidelines on the Gastrointestinal Evaluation of Iron Deficiency ...
https://doi.org/10.1053/j.gastro.2020.06.046
Gastroenterology Ko CW, Siddique SM et. al.

Aug 19th, 2020 - AGA Clinical Practice Guidelines on the Gastrointestinal Evaluation of Iron Deficiency Anemia.|2020|Ko CW,Siddique SM,Patel A,Harris A,Sultan S,|blood,diagnosis,epidemiology,etiology,standards,standards,diagnostic imaging,metabolism,pathology,stan...

Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH...
https://doi.org/10.1200/JCO.18.02142
Journal of Clinical Oncology : Official Journal of the Am... Bohlius J, Bohlke K et. al.

Apr 11th, 2019 - To update the American Society of Clinical Oncology (ASCO)/American Society of Hematology (ASH) recommendations for use of erythropoiesis-stimulating agents (ESAs) in patients with cancer. PubMed and the Cochrane Library were searched for randomiz...

see more →

Drugs  708 results see all →

Clinicaltrials.gov  2 results

Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301)
https://clinicaltrials.gov/ct2/show/NCT00474747

Oct 27th, 2017 - BACKGROUND: Aplastic anemia (AA) remains a life-threatening illness. Treatment options include supportive care (transfusions, growth factors, etc.), immunosuppression therapy and stem cell transplantation. Only the latter two have favorably impact...

Multicenter Transplant Study for Fanconi Anemia
https://clinicaltrials.gov/ct2/show/NCT01082133

Jun 29th, 2016 - The trial proposed is a single arm phase II multicenter treatment protocol designed to examine engraftment, toxicity, graft-versus-host disease, and ultimate disease-free survival following a novel cytoreductive regimen including busulfan, cycloph...

see more →

News  1,729 results

New Era for Targeting HER2 Beckons in Breast Cancer and Beyond
https://www.onclive.com/view/new-era-for-targeting-her2-beckons-in-breast-cancer-and-beyond

Aug 25th, 2021 - Precision medicine advancements are opening a new chapter in the development of anticancer therapies that target the HER2 pathway, resulting in 3 approvals for breast cancer in less than a year and raising hopes for attacking other cancer types. ...

Talking Tumors: Exploring Management Strategies in Multiple Myeloma
https://www.onclive.com/view/talking-tumors-exploring-management-strategies-in-multiple-myeloma

Aug 17th, 2021 - This week, we spoke with Nina Shah, MD, an associate professor of medicine in the Department of Medicine at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, along with Sandy Wong, MD, an assistant clinic...

NCCN Guidelines Include an Abundance of Options Across Multiple Myeloma Paradigm
https://www.onclive.com/view/nccn-guidelines-include-an-abundance-of-options-across-multiple-myeloma-paradigm

Aug 17th, 2021 - The National Comprehensive Cancer Network (NCCN) guidelines for the management of frontline and relapsed/refractory multiple myeloma were updated to incorporate novel agents and combination strategies, providing a wide range of category 1 recommen...

OPTIC Primary Analysis: a Dose-Optimization Study of 3 Starting Doses of Ponatinib in CML Treatment
https://www.onclive.com/view/optic-primary-analysis-a-dose-optimization-study-of-3-starting-doses-of-ponatinib-in-all-treatment

Aug 11th, 2021 - Data from the following presentations are discussed: OPTIC primary analysis: A dose-optimization study of 3 starting doses of ponatinib (PON). (Cortes, ASCO 2021 Abstract 7000) Efficacy: In this phase 2 dose optimization trial, treatment or expo...

The VISION Study in Metastatic CRPC
https://www.onclive.com/view/the-vision-study-in-metastatic-crpc

Jul 26th, 2021 - Scott T. Tagawa, MD, MS, FACP: The VISION trial was a study of patients with pretreated, metastatic, castration-resistant prostate cancer. The study was designed for patients who really had no other options. The minimum requirements for inclusion ...

see more →

Patient Education  15 results see all →